Fibrogen Inc CS (FGEN)

$9.71 +0.69 (7.65%)
Market Cap 39.28M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio 0.00
Volume 34,200
Avg Vol 36,202
Day's Range N/A - N/A
Shares Out 4.05M
Stochastic %K 97%
Beta 0.77
Analysts Sell
Price Target $43.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 17 at 7:17 AM
$FGEN links to news about KYNB (formerly FGEN) https://docs.google.com/spreadsheets/d/1cDIJN25xCpojie2eHDYLpphzN-PcizI_-TDIf0q7b9Q/edit?gid=0#gid=0
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 14 at 9:12 PM
$FGEN (BUY and HOLD) The trials compared 6 HIF-PHIs (roxadustat, daprodustat, vadadustat, molidustat, enarodustat, and desidustat) against erythropoiesis-stimulating agents (ESAs) or placebo. Treatment duration ranged from 4 to 104 weeks. Mean patient ranged from 48 to 72 years or older. For increasing hemoglobin levels, roxadustat ranked highest, particularly in the dialysis.
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 14 at 9:00 PM
$FGEN let's go!!!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 14 at 8:49 AM
$FGEN For increasing hemoglobin levels, roxadustat ranked highest, particularly in the dialysis population, compared with ESA (mean difference = +0.38 g/dL; 95% CI: +0.06 to +0.70) and placebo (+1.79 g/dL; 95% CI: +1.42 to +2.16); it also raised serum iron. https://www.hematologyadvisor.com/news/hif-phi-chronic-kidney-disease-ckd-vary-efficacy-safety-treatment-risk/
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 12 at 7:22 PM
$FGEN my first KYNB purchase. I am done buying FGEN.
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 12 at 3:36 AM
$FGEN let's have a nice green positive week.
1 · Reply
trader013
trader013 Jan. 9 at 4:33 PM
$FGEN Let's change the name to Kyntra Bio Inc... Ha!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 9 at 10:49 AM
$FGEN Here is the official press release dated January 7, 2026, which mentions: https://www.globenewswire.com/news-release/2026/01/07/3214424/33525/en/FibroGen-Rebrands-as-Kyntra-Bio-to-Reflect-a-New-Era-of-Focus-and-Momentum.html It explicitly says: "We have submitted to the US Food and Drug Administration the protocol of the main phase 3 clinical trial of the drug roxadustat for the treatment of anemia in patients with low-risk MDS and high blood transfusion load." This is the main news with the rebranding, which confirmed the submission of the protocol (apparently at the end of 2025, as planned). Now we are waiting for news from the FDA.
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 8 at 4:48 PM
$FGEN https://www.kyntrabio.com/
0 · Reply
AcaGold
AcaGold Jan. 8 at 12:45 PM
$FGEN Someone please explain how the "rebranding" (name and symbol changes) improves or clarifies anything about the company.
2 · Reply
Latest News on FGEN
No data available.
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 17 at 7:17 AM
$FGEN links to news about KYNB (formerly FGEN) https://docs.google.com/spreadsheets/d/1cDIJN25xCpojie2eHDYLpphzN-PcizI_-TDIf0q7b9Q/edit?gid=0#gid=0
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 14 at 9:12 PM
$FGEN (BUY and HOLD) The trials compared 6 HIF-PHIs (roxadustat, daprodustat, vadadustat, molidustat, enarodustat, and desidustat) against erythropoiesis-stimulating agents (ESAs) or placebo. Treatment duration ranged from 4 to 104 weeks. Mean patient ranged from 48 to 72 years or older. For increasing hemoglobin levels, roxadustat ranked highest, particularly in the dialysis.
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 14 at 9:00 PM
$FGEN let's go!!!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 14 at 8:49 AM
$FGEN For increasing hemoglobin levels, roxadustat ranked highest, particularly in the dialysis population, compared with ESA (mean difference = +0.38 g/dL; 95% CI: +0.06 to +0.70) and placebo (+1.79 g/dL; 95% CI: +1.42 to +2.16); it also raised serum iron. https://www.hematologyadvisor.com/news/hif-phi-chronic-kidney-disease-ckd-vary-efficacy-safety-treatment-risk/
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 12 at 7:22 PM
$FGEN my first KYNB purchase. I am done buying FGEN.
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 12 at 3:36 AM
$FGEN let's have a nice green positive week.
1 · Reply
trader013
trader013 Jan. 9 at 4:33 PM
$FGEN Let's change the name to Kyntra Bio Inc... Ha!
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 9 at 10:49 AM
$FGEN Here is the official press release dated January 7, 2026, which mentions: https://www.globenewswire.com/news-release/2026/01/07/3214424/33525/en/FibroGen-Rebrands-as-Kyntra-Bio-to-Reflect-a-New-Era-of-Focus-and-Momentum.html It explicitly says: "We have submitted to the US Food and Drug Administration the protocol of the main phase 3 clinical trial of the drug roxadustat for the treatment of anemia in patients with low-risk MDS and high blood transfusion load." This is the main news with the rebranding, which confirmed the submission of the protocol (apparently at the end of 2025, as planned). Now we are waiting for news from the FDA.
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 8 at 4:48 PM
$FGEN https://www.kyntrabio.com/
0 · Reply
AcaGold
AcaGold Jan. 8 at 12:45 PM
$FGEN Someone please explain how the "rebranding" (name and symbol changes) improves or clarifies anything about the company.
2 · Reply
Value10
Value10 Jan. 8 at 2:25 AM
$FGEN I like the Re-Branding… a lot! And, nicely timed at the beginning of the Year… and that explains their weak Website, since they knew they were going to Re-Brand. Now, I think they may raise more Cash with a Stock Sale and Dilution of Shares… this is not always bad, if timed well. New Brand, New FDA Reports late 2026, New Website, New Pitch… maybe they could both Raise Cash AND Raise the Stock… the stock is already SO undervalued, so if they Raised $200 Million in a Stock Sale with a good Underwriter, the Stock may take off…
2 · Reply
Save4theFuture
Save4theFuture Jan. 8 at 1:09 AM
$FGEN open at $11 tomorrow
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 7 at 2:29 PM
$FGEN A recent major bio stock name change is FibroGen, Inc. (FGEN) rebranding to Kyntra Bio (KYNB), effective January 8, 2026, signaling a sharpened focus on oncology and rare diseases after transforming its business. Whether it's "good" or "bad" depends on the company's success, but it's often a positive sign of strategic renewal in biotech, reflecting new goals and management.
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 7 at 1:11 PM
$FGEN ?????? The changed names
1 · Reply
AcaGold
AcaGold Jan. 7 at 12:36 PM
$FGEN These "rebrandings" don't usually turn out well. Bruce Jenner, for example.
2 · Reply
AcaGold
AcaGold Jan. 7 at 12:34 PM
$FGEN https://www.globenewswire.com/news-release/2026/01/07/3214424/33525/en/FibroGen-Rebrands-as-Kyntra-Bio-to-Reflect-a-New-Era-of-Focus-and-Momentum.html
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 6 at 2:33 PM
$FGEN Mkt Cap $36.13M what a joke, should be at least 100M
0 · Reply
trader013
trader013 Jan. 5 at 4:07 PM
$FGEN Let's rock n roll... very
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 5 at 1:01 PM
$FGEN let's go!!!
1 · Reply
Waikiki2010
Waikiki2010 Jan. 4 at 6:30 PM
$FGEN Expecting news of the phase 3 protocol filing for Roxadustad to the FDA any time now this coming week, if approved it will be a 8 to16 weeks trial and then... a decision. Good luck to all fellow shareholders.
3 · Reply
FallenAngelX
FallenAngelX Jan. 3 at 3:34 AM
$FGEN This not moving much need volune
0 · Reply
FallenAngelX
FallenAngelX Jan. 3 at 3:33 AM
$FGEN
0 · Reply